US spends $275M more on Eli Lilly's Covid mAb as about half of supplies have been administered so far
Eli Lilly said Wednesday that the US government has re-upped its supply of the Covid-19 treatment bebtelovimab, which is the last monoclonal antibody or mAb treatment left to attack this latest strain of Omicron.
The US will pay $275 million for 150,000 doses of bebtelovimab, which comes out to about $1,833 per dose. Back in February, the US bought 600,000 doses for $1.08 billion, or about $1,800 per dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.